Mesothelin is a cell surface antigen of unknown function that is strongly expressed in mesothelial cells. Although it was reported in 1992 that immunostaining with the K1 anti-mesothelin antibody could be very useful in distinguishing between epithelioid mesotheliomas and pulmonary adenocarcinomas, no further studies have been published on the value of this marker in the diagnosis of mesotheliomas. To determine whether mesothelin can assist in discriminating epithelioid mesotheliomas from lung adenocarcinomas or from other carcinomas metastatic to the serosal membranes, 55 mesotheliomas (44 epithelioid, 3 biphasic, and 8 sarcomatoid), 48 carcinomas of the lung (31 adenocarcinomas, 17 squamous carcinomas), and 86 nonpulmonary adenocarcinomas (14 ovary, 5 peritoneum, 9 endometrium, 11 pancreas, 4 stomach, 16 colon, 12 breast, 9 kidney, 4 thyroid, and 2 prostate) were investigated for mesothelin expression using the recently available 5B2 antimesothelin monoclonal antibody. 
A well-known problem in surgical pathology is the distinction of pleural mesothelioma from peripheral pulmonary adenocarcinoma involving the pleura or from a metastatic adenocarcinoma originating from a distant organ and presenting as a tumor of unknown origin. This differential diagnosis, however, has been greatly facilitated by the use of immunohistochemical markers. Because a specific marker for mesothelioma has not yet been identified, the immunohistochemical diagnosis depends on the use of panels of markers that until recently were composed primarily of antibodies that frequently reacted with adenocarcinomas but not with mesotheliomas (1) (2) (3) (4) . Since the mid-1990s, however, a large number of antibodies that commonly react with mesotheliomas, but not with adenocarcinomas, have become available (3, (5) (6) (7) (8) (9) (10) (11) (12) .
In 1992, using the K1 anti-mesothelin monoclonal antibody on frozen tissue specimens, Chang et al. (13) reported mesothelin expression in all of 15 epithelioid mesotheliomas but in none of 23 pulmonary adenocarcinomas. On the basis of this observation, those investigators concluded that mesothelin immunostaining could be useful in discriminating between these two malignancies. Despite such promising results, no other investigations on the value of mesothelin in the diagnosis of mesothelioma have been published, and the Chang et al. (13) observation has remained unconfirmed. An anti-mesothelin monoclonal antibody capable of reacting on routinely fixed and processed specimens has recently become commercially available. The purpose of this study is to investigate the value of this antibody in the diagnosis of mesothelioma.
MATERIALS AND METHODS
The material used in this study was obtained from the files of the Department of Pathology at the University of Texas M.D. Anderson Cancer Center and is listed in Table 1 . It consists of 55 unequivocal mesotheliomas (44 epithelioid, 8 sarcomatoid, 3 biphasic), 48 primary lung carcinomas (31 adenocarcinomas, 17 squamous carcinomas), and 86 nonpulmonary carcinomas, which consisted of 14 nonmucinous carcinomas of the ovary (11 serous and 3 endometrioid), 5 primary peritoneal serous carcinomas, 9 endometrial adenocarcinomas, 11 pancreatic ductal adenocarcinomas, 16 colonic adenocarcinomas, 4 gastric adenocarcinomas, 12 breast carcinomas, 9 renal cell carcinomas, 4 papillary thyroid carcinomas, and 2 prostatic adenocarcinomas. The lung adenocarcinomas were diagnosed using the World Health Organization's criteria (14) . Fifteen were acinar, 8 were papillary, 6 were solid with mucin production, and 2 were bronchioloalveolar. For all of the mesotheliomas, the diagnosis was made using currently accepted histologic criteria on hematoxylin-and-eosin stained sections combined with immunohistochemical, ultrastructural, and clinical features. All of these cases showed strong reactivity for calretinin and cytokeratin 5/6 but were negative for carcinoembryonic antigen, B72.3, and MOC-31, findings that are considered to be supportive of the diagnosis of mesothelioma (15) . Immunoperoxidase studies were performed on formalin-fixed, paraffin-embedded tissue sections using the avidin-biotin-peroxidase complex (ABC) method in a DAKO AutoStainer (Carpinteria, CA). The primary antibody used was the 5B2 anti-mesothelin monoclonal antibody (Novocastra, Newcastle-on-Tyne, UK; 1:30 dilution). The immunoperoxidase staining was done using the LSAB2 peroxidase kit (DAKO). To enhance the immunostaining, a heat epitope retrieval procedure was performed using a Blackand-Decker (Shelton, CT) vegetable steamer. Briefly, deparaffinized sections were placed in a thermoresistant container filled with a 10:1 solution of Tris-EDTA buffer, pH 8.0, steamed for 45 minutes, then cooled for 20 minutes before immunostaining. The antigen-antibody immunoreaction was visualized using 3,3'-diaminobenzidene tetrahydrochloride as chromogen. To evaluate the specificity of the immunoreaction, known positive and negative tissue sections were used as controls. In addition, sections of the tumors were stained with the universal negative control, mouse (DAKO). The grading of the immunostaining was performed on a sliding scale of 1ϩ to 4ϩ according to the percentage of reactive cells (trace ϭ Ͻ1%; 1ϩ ϭ 1-25%; 2ϩ ϭ 26 -50%; 3ϩ ϭ 51-75%; 4ϩ ϭ Ͼ76%).
RESULTS
All 44 (100%) of the epithelioid mesotheliomas exhibited reactivity for mesothelin on the cell membranes. This was particularly strong, thick, and uniform along the apical surface ( Fig. 1,A-B) . A similar staining pattern was present in the epithelioid component of the three biphasic tumors. No reactivity was seen in any of the eight sarcomatoid mesotheliomas or in the spindle cell component of the biphasic tumors.
Twelve (39%) of the 31 lung adenocarcinomas exhibited mesothelin reactivity. In 6 of the tumors, the staining was primarily along the apical surface of the cells; in 5, it was mixed membranous and cytoplasmic; and in 1, it was exclusively cytoplasmic (Fig. 2,A-B) . Among the nonpulmonary carcinomas, reactivity was seen in 14 of 14 originating in the ovary, 5 of 5 in the peritoneum, 10 of 11 in the pancreas, 6 of 9 in the endometrium, 5 of 16 in the colon, and 2 of 4 in the stomach. The staining in the ovarian carcinomas and the primary peritoneal serous carcinomas was usually strong and exhibited a similar pattern to that seen in the mesotheliomas. In the papillary areas, the reactivity mainly occurred along the apical surfaces of the neoplastic cells, whereas in the solid areas, the entire cell membrane was often involved (Fig. 3,A-B) . In the other adenocarcinomas, although the staining was primarily apical, some cells also presented strong cytoplasmic positivity (Fig. 4) . Only 3 of the 17 squamous carcinomas of the lung were mesothe- lin positive. In all of these cases, the staining was membranous and occurred in small, focal areas of the tumor (5 to 10% of the neoplastic cells).
The immunohistochemical results are summarized in Table 1 .
DISCUSSION
Mesothelin is a differentiation antigen that was originally described as the antigenic target of the K1 monoclonal antibody (16, 17) . This antibody was generated using the OVCAR-3 ovarian carcinoma cell line. It is now known that mesothelin is a 40-kDa glycosyl-phosphatidylinositol (GPI)-linked glycoprotein that is synthesized as a 69 kDa precursor that is enzymatically processed into an N-terminal-secreted form of molecular mass 30 kDa and a GPI-linked membrane-bound form of 40 kDa (18) . The secreted form is identical to the megakaryocyte-potentiating factor (19) . It is, however, the GPI-linked membrane form that has generated the most interest as a potential immunohistochemical marker in tumor diagnosis (20) .
Because mesothelin is strongly expressed in normal mesothelial cells and in mesotheliomas, Chang et al. (13) investigated the potential use of this protein as an immunohistochemical marker for distinguishing between epithelioid mesotheliomas and pulmonary adenocarcinomas. Those investigators reported strong mesothelin expression in all of the epithelioid mesotheliomas investigated using the K1 anti-mesothelin antibody on frozen tissue specimens, whereas all of the pulmonary adenocarcinomas were negative for this marker. On the basis of these results, it was concluded that the K1 antibody was a useful positive mesothelial marker for discriminating between these two malignancies. These results are in contrast to those obtained in the present investigation using the 5B2 anti-mesothelin monoclonal antibody that has only recently become commercially available. In this study, even though mesothelin expression was demonstrated in all 44 (100%) epithelioid mesotheliomas, it was also found to occur in 39% of the lung adenocarcinomas. Some differences in the staining pattern were noticed, however. Although the reactivity in the mesotheliomas was more often membranous, strong, and diffuse, in the lung adenocarcinomas it was usually focal, sometimes mixed membranous and cytoplasmic, or predominantly cytoplasmic. Despite these differences, the fact that more than one third of the lung adenocarcinomas were mesothelin positive and 12 mesotheliomas exhibited focal reactivity (1ϩ or 2ϩ) significantly limit the value of mesothelin immunostaining in discriminating between these malignancies. Only one of the four sarcomatoid mesotheliomas stained by Chang et al. (13) with the K1 anti-mesothelin antibody was reported as being positive in only 20% of the neoplastic cells. In the present study, all eight sarcomatoid mesotheliomas, as well as the spindle cell component of the three biphasic mesotheliomas, were mesothelin negative. This finding indicates that mesothelin immunostaining has no utility in the diagnosis of sarcomatoid mesotheliomas.
A great variation of mesothelin expression was found among the nonpulmonary adenocarcinomas investigated in the present study. All 14 nonmucinous ovarian carcinomas and all 5 peritoneal serous carcinomas investigated were strongly mesothelin positive. Although the percentage of ovarian carcinomas exhibiting mesothelin expression is higher than was obtained by Chang et al. (17) , who reported mesothelin expression in 10 of 15 (66%) nonmucinous ovarian carcinomas using the K1 antibody, it confirms that mesothelin immunostaining has no utility for distinguishing between epithelioid mesotheliomas and primary peritoneal serous carcinomas or metastatic ovarian carcinomas to the serosal membranes.
Besides ovarian carcinomas, adenocarcinomas of the pancreas were another malignancy that was found to frequently express mesothelin in the present study. Ten of the 11 pancreatic adenocarcinomas investigated were mesothelin positive, and in most of these cases, the staining was strong and diffuse. These results are similar to those reported by Argani et al. (20) who, using the same anti-mesothelin antibody employed in the present investigation, demonstrated mesothelin expression in all 60 of their pancreatic adenocarcinomas. In that study, the staining was reported to be focal (Ͻ25% of the tumor cells) in 10 cases (17%), diffuse (Ͼ75% of the tumor cells) in 18 cases (30%), and in the remaining 32 cases, reactivity was seen in 25 to 75% of the neoplastic cells. Also in that investigation, the normal pancreas in 52 of the 60 cases was reported as being essentially nonreactive, whereas in the remaining 8, a faint "blush" staining in scattered pancreatic ducts was observed. This observation was considered to be important because it suggested that strong mesothelin immunostaining may assist in separating neoplastic from non-neoplastic ductal epithelial cells in small biopsies and cytologic specimens. In addition to adenocarcinomas of the lung, pancreas, and ovary, those originating in the endometrium, stomach, and colon were also found to express mesothelin. No reactivity, however, was seen in any of the adenocarcinomas of the breast, kidney, thyroid, or prostate.
Only 3 (18%) of 17 squamous carcinomas of the lung in the present investigation exhibited mesothelin reactivity, and the staining in these cases was limited to small areas of the tumor. This finding is in contrast to that of Chang et al. (21) , who were able to demonstrate mesothelin expression with the K1 antibody in 8 (80%) of 10 squamous carcinomas of the lung. The staining obtained in those cases was usually strong, in contrast to the results seen in the present study, in which the reactivity was limited to only 5 to 10% of the neoplastic cells.
In conclusion, the results in the present study confirm previous reports that indicate that mesothelin is strongly expressed in epithelioid mesotheliomas and ovarian carcinomas. In contrast to previous reports, however, this study has found that mesothelin can also be expressed in lung adenocarcinomas, thus limiting the practical value of this marker for discriminating between epithelioid mesotheliomas and pulmonary adenocarcinomas. Although mesothelin is not recommended for inclusion in the standard immunohistochemical panel used to assist in distinguishing between these malignancies (15) , it may have some utility in those cases in which the results are equivocal. Because of 
